Astria Therapeutics (US:ATXS) — Company Overview, News & Financial Data
Astria Therapeutics develops therapies for allergies and immune diseases, focusing on patient-centric solutions and clinical advancements.
Astria Therapeutics
Astria Therapeutics (NASDAQ:ATXS) focuses on developing transformative therapies for allergies and immune diseases. The company is currently working on several innovative projects, including a promising treatment for hereditary angioedema, a rare and life-threatening genetic condition. With a commitment to improving patient outcomes, Astria aims to lead the way in novel, patient-centric solutions. Their main objective is to advance their pipeline of treatments through clinical development, ensuring they address unmet medical needs within their target markets. Astria Therapeutics operates with a vision to significantly enhance the quality of life for patients suffering from debilitating allergic and immune conditions, showcasing a dedicated approach to healthcare innovation.
Snapshot
Operations
Products and/or services of Astria Therapeutics
- STAR-0215 is a monoclonal antibody designed for hereditary angioedema to provide long-lasting prevention, aiming for monthly or less frequent dosing.
- Preclinical pipeline targeting complement-mediated diseases with a focus on rare conditions, utilizing proprietary technology to block harmful complement system components.
- Research on innovative biologics for autoimmune and inflammatory diseases, exploring novel targets to treat conditions with high unmet medical need.
- Development of therapies aimed at addressing C1 esterase inhibitor deficiency, exploring next-generation treatments to improve patient outcomes.
- Collaboration with academic and industry partners to accelerate the development of treatments for rare diseases, leveraging expertise in complement biology.
- Investment in cutting-edge drug discovery platforms to expedite the identification and development of novel therapeutics for complement-mediated disorders.
Astria Therapeutics executive team
- Ms. Jill C. Milne Ph.D.Co-Founder, CEO, President & Director
- Ms. Keri McGrailChief Human Resources Officer
- Mr. John RueschSenior Vice President of Pharmaceutical Sciences & Technical Operations
- Ms. Rafif DagherSenior VP and Head of Discovery, Nonclinical Development & Translational Research